Chak-yu So1, MBChB; Shuang Li2, MD; Guo-hua Fu3, MD; Wei Chen2, MD; Kevin Ka-ho Kam1, MBChB; Alex Pui-Wai Lee1, MBChB, MD; Hui-min Chu3, MD; Ya-wei Xu2, MD, PhD; Bryan P Yan1, MBBS; Yat-yin Lam1,4, MBBS, MD
1. Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, China; 2. Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; 3. Department of Cardiology, Ningbo First Hospital, Ningbo, China; 4. Hong Kong Asia Heart Center, Canossa Hospital, Hong Kong SAR, Hong Kong, China
The commonly used left atrial appendage (LAA) occlusion (LAAO) devices, the WATCHMAN™ (Boston Scientific, Marlborough, MA, USA) and the AMPLATZER™ Amulet™ (Abbott Vascular, Santa Clara, CA, USA), both rely on oversizing for stabilisation. Therefore, occluding large LAA (ostium ≥31 mm for the WATCHMAN or landing zone ≥31 mm for the AMPLATZER Amulet) is not possible. The LAmbre™ device (Lifetech Scientific [Shenzhen] Co., Ltd. Shenzhen, China) has an additional stabilisation mechanism which catches the LAA trabeculations using its eight claws1. This potentially allows LAmbre to occlude a large LAA with an ostium up to 40 mm, ...
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
Interventions for strokeLAA closure
Read next article
Transoesophageal echocardiography guidance with paediatric probes in adults undergoing left atrial appendage occlusion